The 'PARADIGM' study was recently presented at ASH 2025 and showed that fit adults with newly diagnosed AML who received azacitidine/venetoclax (vs 'intensive 7+3 chemotherapy') had better EFS/QoL with greater proportion of patients who successfully got to a stem cell transplant. Provided that the OS data is yet to mature, do these results change your current clinical practice?